http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2008001872-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c98babf0d86f960b139cdb7401f3420f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate | 2006-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f849b4809f21ea3a06465bd8a515815 |
| publicationDate | 2008-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2008001872-A |
| titleOfInvention | A NEW SEQUENCE OF NUCLEIC ACID THAT CODIFIES A NEW NOVEL PROTEIN OF CANDIDA ALBICANS AND USES OF THE SAME. |
| abstract | An antifungal target drug comprising a Candida albicans polypeptide sequence, referred to as CaSRF1, is described herein, which is involved in the regulation of morphogenetic transformation and virulence in response to the absorption of its immune response cells. model receiver. The gene is unique in its ability to affect virulence-associated morphogenesis in vivo although it is not required for in vitro morphogenesis. The location of the putative membrane and its effect on the integrity of the cell wall indicates that it is an ideal anti-candida target drug due to its easy prognostic access ability to drive molecules / chemical agents and its ability to affect virulence . |
| priorityDate | 2005-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.